Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out- licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

I led the commercialization of Abzena’s proprietary ADC technologies, including the ThioBridge™ ADC conjugation technology, and of Abzena's synthetic and bioconjugation chemistry services provided from both the UK and US sites, including: - Synthetic chemistry services including custom synthesis at mg scale through to cGMP manufacturing of highly potent cytotoxic drugs - Extensive ADC screening toolbox of linkers, spacers and cytotoxic payloads including Auristatins (MMAE, MMAF, PE, Dolastatin-10), Maytansines (DM-1, DM-4, >10 derivatives), Tubulysins, PBDs, Duocarmycins, PNU-159682, Calicheamicin, Topotecans, etc. - Conjugation services from research scale to manufacturing of ADCs - Expertise in all types of conjugation including lysine conjugation, natural and engineered cysteine conjugation, non-natural amino acid and enzymatic conjugation approaches - PEGylation and PK optimisation of biologics - Extensive analytical capabilities including HPLC method development, 1D-NMR analysis (300 MHz, 500 MHz, 1H,13C, 31P, 19F, multidimensional), 2-D NMR analysis (gCOSY, ROESY, TOCSY, gHMQC, multiplicity-edited HSQC, CH-only HSQC, gHSQCAD-TOCSY, gHMBCAD), Protein NMR, complex LC-MS analysis, GC-MS with headspace for residual solvent analysis, Chiral separations (analytical method development and preparative separation)Abzena’s other services and technologies include: - Immunogenicity assessment and bespoke immunology studies including cytokine profiling and checkpoint inhibitor analysis - Protein engineering and optimisation including Composite Human Antibody™ humanisation technology clinically proven to generate non-immunogenic antibodies - Composite Proteins™ technology for engineering therapeutic proteins with reduced immunogenicity - Manufacturing cell line development (in CHO, NS0 and SP2/0 cell lines) - cGMP Biologics manufacturing for phase I and phase II

Led the commercialization of the ThioBridge™ ADC technology and other bioconjugation technologies and services. Strategic reevaluation and delivery of the business development model for bioconjugation services and technologies. Integration of chemistry services between US and UK sites of Abzena as well as the integration of complementary services across Abzena to deliver a turn-key, complete solution for the development of ADCs. Highlights include:• Led the commercialization of conjugation services, increasing revenues over 15-fold in three years. • Supported entire deal making process from sourcing the opportunity, leading it through a preclinical evaluation, to converting it to a licensing opportunity and then working closely with SVP IP, Legal and Commercial Affairs and external counsel to draft, negotiate and successfully conclude a research collaboration and license with Halozyme Therapeutics, a US West Coast innovative biotech company, for the ThioBridgeTM technology. This was the biggest deal of the Abzena Group at the time, with a total term-sheet value of $150 million and the first ThioBridge™ ADC currently advancing towards the clinic. This was followed by a second research collaboration and license with innovative San Diego-based biotech company for the ThioBridgeTM technology for up to 10 product candidates and a total term-sheet value of $300 million.• Successfully scouted for new opportunities, established new business relationships with Biotech and Pharma companies in Europe, the US and the Far East.• Negotiated and concluded over 40 evaluation agreements and extensions, some with Heads of Terms, with companies ranging from virtual biotech to major Pharma. • Initiated negotiations for a research collaboration and license with innovative biotech company for the ThioBridgeTM technology for multiple product candidates.

Abzena provides an extensive suite of services and technologies to enable the development of better biopharmaceutical products.Our range of technologies for the site specific conjugation of cytotoxic drugs to create more homogeneous and stable antibody drug conjugates (ADCs) and our reagents and polymers for optimising the pharmacokinetics and pharmacodynamics of proteins, peptides and antibodies enable you to modify your therapeutic product to produce the desired clinical benefit. In addition, we provide complementary immunogenicity testing, antibody humanisation, protein engineering and manufacturing cell line development technologies through Antitope, our wholly owned subsidiary, to improve the safety and reduce the risk of loss of efficacy of biopharmaceutical candidates before they enter the clinic.